A large body of research has identified HIF1A-AS2 as a tumor-related lncRNA and acts as a tumor promoter, as demonstrated by in vitro and in vivo experiments, such as in gastric cancer (GC), breast cancer (BC), bladder cancer, osteosarcoma (OS) and renal cancer (RC) (12–16). Here, HIF1A is linked to breast cancer.